VICP Vicapsys Life Sciences, Inc.
Pharmaceutical Preparations · OTC · SEC CIK 1468639 · Fiscal year ends 12/31
Financial factors as of 2024-09-30 (2024Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-24.8%
TTM EPS YoY0.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-904.2%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets3,053.8%
Debt / equity—
Current ratio0.03x
Interest coverage-62.88x
Cash quality & payout
Operating cash flow / net income0.09x
Accruals ratio-819.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2024Q32024-09-30 | 2024Q22024-06-30 | 2024Q12024-03-31 | 2023Q4*2023-12-31 | 2023Q32023-09-30 | 2023Q22023-06-30 | 2023Q12023-03-31 | 2022Q4*2022-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $3,746 | $10,000 | $344 | $0 | $3,267 | $2,000 | $10,000 | $0 |
| SG&A expense | $4,116 | $2,841 | $34,864 | $32,355 | $26,925 | $15,313 | $3,763 | $18,988 |
| Operating income | -$198,862 | -$181,841 | -$204,255 | -$527,207 | -$175,423 | -$135,693 | -$211,277 | -$492,605 |
| Interest expense | $36,645 | $8,250 | -$36,517 | $9,309 | $9,954 | — | — | — |
| Pretax income | -$235,507 | -$190,091 | -$327,072 | -$594,803 | -$240,340 | -$135,693 | -$211,277 | -$492,605 |
| Net income | -$235,507 | -$190,091 | -$327,072 | -$594,803 | -$240,340 | -$135,693 | -$211,277 | -$492,605 |
| EPS (basic) | -0.01 | -0.01 | -0.01 | — | -0.01 | 0.00 | -0.01 | — |
| EPS (diluted) | -0.01 | -0.01 | -0.01 | — | -0.01 | 0.00 | -0.01 | — |
| Weighted avg. shares (diluted) | 34.33M | 34.19M | 32.07M | — | 34.41M | 35.31M | 34.59M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $89,569 | — | — | $9,422 | $53,532 | $231,277 | $4,140 | $14,097 |
| Current assets | $89,569 | — | — | $39,656 | $208,486 | $378,147 | $63,293 | $72,021 |
| Total assets | $89,569 | — | — | $39,656 | $208,486 | $378,147 | $63,293 | $72,021 |
| Current liabilities | $2.74M | $2.45M | $2.26M | $1.97M | $1.54M | $1.47M | $1.20M | $1.02M |
| Short-term debt | — | $12,546 | $12,546 | $18,712 | $36,789 | $54,230 | — | — |
| Total liabilities | $2.74M | — | — | $1.97M | $1.54M | $1.47M | $1.20M | $1.02M |
| Shareholders' equity | -$2.65M | -$2.45M | -$2.26M | -$1.93M | -$1.33M | -$1.09M | -$1.14M | -$950,791 |
| Shares outstanding | 32.37M | 32.07M | 32.07M | 32.07M | 32.07M | 31.19M | 31.19M | 31.19M |
| Cash flow statement | ||||||||
| Operating cash flow | -$40,431 | $6,166 | -$9,422 | -$82,054 | -$107,410 | -$218,103 | -$9,957 | $2,888 |
| Financing cash flow | $130,000 | — | — | $37,944 | -$70,335 | — | — | -$15,001 |
| Stock-based compensation | — | — | — | $0 | $0 | $0 | $20,697 | $62,093 |
Free plan shows the latest 8 periods; Pro shows all 23 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.